|
|
Vaccine Detail
|
AMA1-C1Alhydrogel + CPG 7909 |
| Vaccine Information |
- Vaccine Name: AMA1-C1Alhydrogel + CPG 7909
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: AMA1-C1 (NIAID, 2006): Apical membrane antigen 1. An 83-kDa antigen that may be involved in the process of erythrocyte invasion (Hodder et al., 2001).
- AMA1 from P. falciparum 3D7
gene engineering:
- Type: Recombinant protein preparation
- Description: An equal mixture of recombinant proteins based on sequences from the FVO and 3D7 P. falciparum, expressed in Pichia pastoris and adsorbed on Alhydrogel. (Malkin et al., 2005)
- Detailed Gene Information: Click Here.
-
Adjuvant:
Alhydrogel®(NIAID, 2006): an aluminium hydroxide (alum) wet gel suspension, increase the efficacy of the vaccine by the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway (He et al., 2015); and CPG-7909(NIAID, 2006): a TLR9 agonist oligodeoxynucleotide that improves the body's reactions to vaccines(Cooper et al., 2004)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccination Protocol: Double blind Phase 1 trial
24 participants were randomly assigned to one of the two groups: 12 volunteers will receive two doses of 80 microgram AMA1-C1/Alhydrogel + 500 microgram CPG; 12 volunteers will receive 80 microgram AMA1-C1/Alhydrogel, both at a 1-month dosing interval. (NIAID, 2006)
|
| References |
Cooper et al., 2004: Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. Journal of clinical immunology. 2004; 24(6); 693-701. [PubMed: 15622454].
He et al., 2015: He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human vaccines & immunotherapeutics. 2015; 11(2); 477-488. [PubMed: 25692535].
Hodder et al., 2001: Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infection and immunity. 2001; 69(5); 3286-3294. [PubMed: 11292751].
Malkin et al., 2005: Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infection and immunity. 2005; 73(6); 3677-3685. [PubMed: 15908397].
NIAID, 2006: Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria [https://clinicaltrials.gov/ct2/show/NCT00414336?term=vaccine&cond=malaria&draw=6]
|
|
